A new TB vaccine for adolescents and adults, developed by IIT and ILS Bhubaneswar, is set for commercialisation.

The vaccine triggers strong immune responses against Mycobacterium tuberculosis and is licensed for commercial development to ...

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the ...

Bhubaneswar and Institute of Life Sciences (ILS) along with National Research Development Corporation (NRDC) o ...

Initial blood work found hints of an infection, and the doctors initially suspected a bacterial skin infection (cellulitis) ...

The HSP Subunit Vaccine candidate, jointly developed by the Institute of Life Sciences (ILS), Bhubaneswar, and the Indian Institute of Technology (IIT) Bhubaneswar, marks a significant advancement in ...

The Global TB Report 2025 released by the World Health Organization (WHO) highlights that India’s TB incidence has reduced ...

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS), along with the ...

Three Indian research institutes have signed an agreement with TechInvention Lifecare Limited for the technology transfer and future commercialisation of a novel TB vaccine candidate<br />The Indian ...

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as reported by the WHO. Ending the TB epidemic by 2030 is a key global health ...

The Indian Institute of Technology and the Institute of Life Sciences, in partnership with TechInvention Lifecare and the National Research Development Corporation, are advancing a novel TB vaccine.

The number of people diagnosed with tuberculosis worldwide rose again last year, eclipsing 2023's record total.